Background
Post-zygotic aneuploidy is the prominent genetic feature of the human brain (1). Genomically mosaic brain results from that the excess of aneuploid neurons due to early developmental disturbances (somatic genome variations), abnormal cell cycle regulation and altered programmed cell death. As the result, aneuploidization of the brain is a likely susceptibility factor (mechanism) for brain disorders including Alzheimer’s disease.
Materials and methods
The proportion of aneuploid cells was determined in brain areas differentially affected by neurodegeneration (prefrontal cortex, hippocampus and cerebellum) by molecular-cytogenetic and immunohistochemical techniques (interphase MFISH, immunoFISH) in brain tissues of individuals with AD and controls as described ealier (2).
Anzeige
Results
Increased levels of aneuploidy (monosomy and trisomy) involving chromosome 21 and chromosome X was observed in AD brain. The high level of aneuploidy involving chromosome 21 was observed in the AD cerebrum and hippocampus. In total, the incidence of abnormal (aneuploid) neural cells was significantly higher in degenerating brain areas (hippocampus, prefrontal cortex) comparing to the less degenerating area (cerebellum).
Conclusions
Our data indicates that AD brain areas subjected to neurodegeneration are more significantly affected by aneuploidy (especially aneuploidy of chromosomes 21 and X). We propose that widespread postzygotic aneuploidization of selected brain areas is a mechanism for AD neurodegeneration. Such area-specific distribution of aneuploidy can be explained by the accumulation of aneuploid cells during postnatal life or abnormal selective pressure against non-aneuploid cells (3). Finally, these data provide for the speculation that acquired neural aneuploidy could be generated during both developing and adult neurogenesis/gliogenesis.
Acknowledgements
Supported by BMBF/DLR (BLR 11/002), the Russian Federation President Grant (MD-4401.2013.7), RFBR 12-04-00215-a.
Open Access
This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License (
https://creativecommons.org/licenses/by/2.0
), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (
https://creativecommons.org/publicdomain/zero/1.0/
) applies to the data made available in this article, unless otherwise stated.